New combo therapy aims to wipe out rectal tumors before surgery
NCT ID NCT04928807
First seen Feb 28, 2026 · Last updated Apr 25, 2026 · Updated 7 times
Summary
This study compares a new treatment approach for locally advanced rectal cancer: short-course radiation followed by chemotherapy and the immunotherapy drug camrelizumab, versus the standard long-course chemoradiation. About 230 adults with stage T3-4 or node-positive rectal cancer will participate. The main goal is to see if the new combination leads to a higher rate of complete tumor disappearance at the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Conditions
Explore the condition pages connected to this study.